HOME >> BIOLOGY >> NEWS
Harbor Branch Oceanographic Institution And Novartis Pharma AG Sign AgreementFor Licensing And Development Of Anti-Cancer Compound, Discodermolide

FT. PIERCE, FL- Harbor Branch Oceanographic Institution, Inc., Fort Pierce, Florida, has entered into an agreement to license its marine-derived, anti-cancer agent, discodermolide, to Novartis Pharma AG, Basle, Switzerland, on an exclusive world-wide basis.

Discodermolide is an anti-cancer compound derived from the marine sponge, Discodermia dissoluta, first collected in 1987 by Dr. Shirley A. Pomponi, Director of Harbor Branch's Division of Biomedical Marine Research. The compound was isolated from the sponge and characterized by Dr. Sarath P. Gunasekera and Dr. Ross E. Longley at Harbor Branch in 1990. Subsequent studies by the Harbor Branch team and collaborators revealed the compound to be a potent, anti-tumor agent that is effective in killing human cancer cells in vitro with a mechanism of action similar to that of the clinical anti-cancer agent Taxol .

Under terms of the license agreement, Harbor Branch grants Novartis exclusive, world-wide rights for the development, use, manufacture and sale of discodermolide for all potential therapeutic indications. Novartis will provide Harbor Branch with funding for continued research on discodermolide, as well as future payments based on developmental milestones and royalties from the sale of the compound as a drug for the treatment of cancer.

J. Seward Johnson, Jr., of Princeton, N.J., Chairman of Harbor Branch, states: "This agreement is the result of over 14 years of drug discovery research at Harbor Branch, and is the culmination of the last 8 years of research on discodermolide by the Harbor Branch team. Given the exciting and promising pre-clinical data on discodermolide and the expertise in drug development which Novartis provides, our hope is that discodermolide will eventually surpass other chemotherapeutic agents as an effective treatment for cancer".

Harbor Branch Oceanographic Institution, Inc. is one of the nation's premi
'"/>

Contact: Shirley A. Pomponi, Ph.D.
dbmr@hboi.edu
(561) 465-2400 X449
Harbor Branch Oceanographic Institution
16-Apr-1998


Page: 1 2

Related biology news :

1. Academy Harbor Consortium releases letter on mercury to President Bush
2. Microorganisms are cleaning up Boston Harbor, UMass study finds
3. 2002 Cold Spring Harbor Laboratory Meetings
4. Harbor Branch scientist aids in Mexico manatee rescue effort
5. Harbor Branch scientists to study predation habits of jellyfish-like animals in Gulf Of Maine
6. Harbor Branch to receive $2.1 million of a $4.9 million multi-institutional grant to discover new natural product leads for cancer chemotherapy
7. Harbor Branch Scientists Discover Bioluminescent Octopus
8. Harbor Branch Web Developers Team With ABC News To Bring Ocean Adventure To A Computer Near You
9. Harbor Branch Web Developers Bring Adventures @Sea To Every Desktop
10. Harbor Branch Oceanographic Trains Displaced Fishermen And Women In New Careers As Aquafarmers
11. Harbor Branch Oceanographic Institutions Aquaculture Division Studies Viability Of Controlled Reproduction Of Southern Flounder In Captivity

Post Your Comments:
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: